Gillian E Caughey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7751772/publications.pdf

Version: 2024-02-01

230014 134545 4,273 101 27 62 citations h-index g-index papers 106 106 106 6661 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2022, 53, 425-435.	1.0	4
2	Cardiac Implantable Electronic Devices: Reoperations and the Competing RiskÂofÂDeath. Heart Lung and Circulation, 2022, 31, 537-543.	0.2	O
3	Hospitalizations Before and After Entry Into Long-Term Care. Journal of the American Medical Directors Association, 2022, , .	1.2	2
4	Provision of a comprehensive medicines review is associated with lower mortality risk for residents of aged care facilities: a retrospective cohort study. Age and Ageing, 2022, 51, .	0.7	7
5	Primary and Secondary Care Related Quality Indicators for Dementia Care Among Australian Aged Care Users: National Trends, Risk Factors, and Variation. Journal of Alzheimer's Disease, 2022, , 1-11.	1.2	3
6	Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients. BMC Cardiovascular Disorders, 2021, 21, 104.	0.7	5
7	Concomitant inpatient prescribing of strong opioids with sedatives: Associations with comorbid conditions. Pharmacology Research and Perspectives, 2021, 9, e00717.	1.1	3
8	Using data linkage for national surveillance of clinical quality indicators for dementia care among Australian aged care users. Scientific Reports, 2021, 11, 10674.	1.6	4
9	Primary healthcare utilisation by older Australians during the COVID â€19 pandemic. Internal Medicine Journal, 2021, 51, 818-820.	0.5	2
10	Medicationâ€related hospital admissions in aged care residents. Australasian Journal on Ageing, 2021, 40, .	0.4	2
11	Hospitalisation for lower respiratory viral infections in older people in residential aged care facilities. Australasian Journal on Ageing, 2021, , .	0.4	1
12	Predictors of shortâ€term hospitalization and emergency department presentations in aged care. Journal of the American Geriatrics Society, 2021, 69, 3142-3156.	1.3	9
13	Documentation of adverse drug reactions to opioids in an electronic health record. Internal Medicine Journal, 2021, 51, 1490-1496.	0.5	8
14	Effect of Dementia on Outcomes After Surgically Treated Hip Fracture in Older Adults. Journal of Arthroplasty, 2021, 36, 3181-3186.e4.	1.5	13
15	Impact of musculoskeletal conditions among those in residential aged care in Australia. Australasian Journal on Ageing, 2021, , .	0.4	O
16	Prevalence of Eye Conditions, Utilization of Eye Health Care Services, and Ophthalmic Medications After Entering Residential Aged Care in Australia. Translational Vision Science and Technology, 2021, 10, 3.	1.1	5
17	The risk of fall-related hospitalisations at entry into permanent residential aged care. BMC Geriatrics, 2021, 21, 686.	1.1	9
18	Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. Journal of Geriatric Oncology, 2020, 11, 114-120.	0.5	27

#	Article	IF	CITATIONS
19	Rationalisation of polypharmacy in practice: a survey of physicians and pharmacists. Journal of Pharmacy Practice and Research, 2020, 50, 233-241.	0.5	3
20	Inclusion of Older People Reflective of Realâ€World Clinical Practice in Cardiovascular Drug Trials. Journal of the American Heart Association, 2020, 9, e016936.	1.6	7
21	Predictors of Mortality in the Older Population: The Role of Polypharmacy and Other Medication and Chronic Disease-Related Factors. Drugs and Aging, 2020, 37, 767-776.	1.3	11
22	The Registry of Senior Australians outcome monitoring system: quality and safety indicators for residential aged care. International Journal for Quality in Health Care, 2020, 32, 502-510.	0.9	33
23	Predictors of unplanned hospitalisation in the older population: The role of polypharmacy and other medication and chronic diseaseâ€related factors. Australasian Journal on Ageing, 2020, 39, e436-e446.	0.4	2
24	Categorization of adverse drug reactions in electronic health records. Pharmacology Research and Perspectives, 2020, 8, e00550.	1.1	18
25	OUP accepted manuscript. International Journal for Quality in Health Care, 2019, 31, 647-653.	0.9	2
26	Implementation of medication-related indicators of potentially preventable hospitalizations in a national chronic disease management program for older patients with multimorbidity. International Journal for Quality in Health Care, 2019, 31, 133-139.	0.9	3
27	External validation of beta-lactam antibiotic allergy assessment tools: implications for clinical practice and workforce capacity. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2094-2095.	2.0	4
28	A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. Cancer Epidemiology, 2019, 63, 101590.	0.8	31
29	Use of non-formulary high-cost medicines in an Australian public hospital. International Journal of Clinical Pharmacy, 2019, 41, 920-931.	1.0	6
30	Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review. Therapeutic Advances in Drug Safety, 2019, 10, 204209861984699.	1.0	31
31	Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. BMJ Open, 2019, 9, e026486.	0.8	8
32	Comprehension and recall from the informed consent process by phase I healthy volunteers before dose administration. Clinical Trials, 2019, 16, 283-289.	0.7	6
33	Concomitant prescribing of opioids and benzodiazepines in Australia, 2012–2017. Medical Journal of Australia, 2019, 210, 39-40.	0.8	9
34	Use of Medicines that May Exacerbate Heart Failure in Older Adults: Therapeutic Complexity of Multimorbidity. Drugs and Aging, 2019, 36, 471-479.	1.3	7
35	Adverse drug reaction classification by health professionals: appropriate discrimination between allergy and intolerance?. Clinical and Translational Allergy, 2019, 9, 18.	1.4	16
36	Prescribing errors and adverse drug reaction documentation before and after implementation of eâ€prescribing using the Enterprise Patient Administration System. Journal of Pharmacy Practice and Research, 2019, 49, 27-32.	0.5	12

#	Article	IF	CITATIONS
37	Medication-related quality of care in residential aged care: an Australian experience. International Journal for Quality in Health Care, 2019, 31, 298-306.	0.9	9
38	Development and Implementation of a Nurse-Led Model of Care Coordination to Provide Health-Sector Continuity of Care for People With Multimorbidity: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2019, 8, e15006.	0.5	1
39	Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing?. Therapeutic Advances in Drug Safety, 2018, 9, 113-121.	1.0	6
40	Tools for Assessment of the Appropriateness of Prescribing and Association with Patient-Related Outcomes: A Systematic Review. Drugs and Aging, 2018, 35, 43-60.	1.3	53
41	Prevalence and changes in analgesic medication utilisation 1 year prior to total joint replacement in an older cohort of patients. Osteoarthritis and Cartilage, 2018, 26, 356-362.	0.6	23
42	Proton pump inhibitors are not associated with inflammatory myopathies: A case control study. Muscle and Nerve, 2018, 58, 855-857.	1.0	3
43	Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. JAMA Internal Medicine, 2018, 178, 1224.	2.6	19
44	Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. Blood, 2018, 132, 3101-3101.	0.6	4
45	Medication use and potentially highâ€risk prescribing in older patients hospitalized for diabetes: a missed opportunity to improve care?. Diabetic Medicine, 2017, 34, 432-439.	1.2	16
46	Disease burden, comorbidity and geriatric syndromes in the Australian aged care population. Australasian Journal on Ageing, 2017, 36, E14-E19.	0.4	28
47	Clinician agreement and influence of medicationâ€related characteristics on assessment of polypharmacy. Pharmacology Research and Perspectives, 2017, 5, e00321.	1.1	9
48	What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 2017, 17, 230.	1.1	1,706
49	Influence of medication risks and benefits on treatment preferences in older patients with multimorbidity. Patient Preference and Adherence, 2017, Volume 11, 131-140.	0.8	16
50	Understanding 30â€day reâ€admission after hospitalisation of older patients for diabetes: identifying those at greatest risk. Medical Journal of Australia, 2017, 206, 170-175.	0.8	20
51	Documentation of penicillin adverse drug reactions in electronic health records: inconsistent use of allergy and intolerance labels. Internal Medicine Journal, 2017, 47, 1292-1297.	0.5	54
52	Apixaban, concomitant medicines and spontaneous reports of haemorrhagic events. Therapeutic Advances in Drug Safety, 2017, 8, 157-164.	1.0	8
53	Uptake of novel oral anticoagulants in Australia. Medical Journal of Australia, 2016, 204, 104-105.	0.8	32
54	Incident osteoarthritis associated with increased allied health services use in †baby boomer†Australian women. Australian and New Zealand Journal of Public Health, 2016, 40, 356-361.	0.8	3

#	Article	IF	CITATIONS
55	Effect of a general practitioner management plan on health outcomes and hospitalisations in older patients with diabetes. Internal Medicine Journal, 2016, 46, 1430-1436.	0.5	15
56	Trends in general practitioner services to residents in aged care. Australian Journal of Primary Health, 2016, 22, 517.	0.4	10
57	Spontaneously reported haemorrhagic adverse events associated with rivaroxaban and dabigatran in Australia. Therapeutic Advances in Drug Safety, 2016, 7, 4-10.	1.0	8
58	Effect of a Multidisciplinary Outpatient Model of Care on Health Outcomes in Older Patients with Multimorbidity: A Retrospective Case Control Study. PLoS ONE, 2016, 11, e0161382.	1.1	20
59	Evaluating medication-related quality of care in residential aged care: a systematic review. SpringerPlus, 2015, 4, 220.	1.2	21
60	Anticholinergic burden in older women: not seeing the wood for the trees?. Medical Journal of Australia, 2015, 202, 91-94.	0.8	25
61	Suboptimal medicationâ€related quality of care preceding hospitalisation of older patients. Medical Journal of Australia, 2015, 203, 220-220.	0.8	8
62	Medicines taken by older Australians after transient ischaemic attack or ischaemic stroke: a retrospective database study. International Journal of Clinical Pharmacy, 2015, 37, 782-789.	1.0	2
63	An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiology and Drug Safety, 2015, 24, 399-405.	0.9	22
64	Guideline Compliance in Chronic Heart Failure Patients with Multiple Comorbid Diseases: Evaluation of an Individualised Multidisciplinary Model of Care. PLoS ONE, 2014, 9, e93129.	1.1	23
65	Use of secondary stroke prevention medicines in Australia: national trends, 2003â€2009. Medical Journal of Australia, 2014, 201, 54-57.	0.8	8
66	Ranibizumab and Risk of Hospitalisation for Ischaemic Stroke and Myocardial Infarction in Patients with Age-Related Macular Degeneration: A Self-Controlled Case-Series Analysis. Drug Safety, 2014, 37, 1021-1027.	1.4	18
67	Development of evidence-based Australian medication-related indicators of potentially preventable hospitalisations: a modified RAND appropriateness method. BMJ Open, 2014, 4, e004625.	0.8	28
68	A Cross-Country Comparison of Rivaroxaban Spontaneous Adverse Event Reports and Concomitant Medicine Use with the Potential to Increase the Risk of Harm. Drug Safety, 2014, 37, 1029-1035.	1.4	17
69	Doubling in Use of Alteplase in Australia between 2003 and 2009. International Journal of Stroke, 2014, 9, E28-E28.	2.9	0
70	Comorbidity Associated With Referral to Pulmonary Rehabilitation in People Hospitalized With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2014, 34, 430-436.	1.2	4
71	The association between co-morbidities and physical performance in people with chronic obstructive pulmonary disease. Chronic Respiratory Disease, 2014, 11, 3-13.	1.0	10
72	Polyandric Acid A, a Clerodane Diterpenoid from the Australian Medicinal Plant <i>Dodonaea polyandra,</i> Attenuates Pro-inflammatory Cytokine Secretion in Vitro and in Vivo. Journal of Natural Products, 2014, 77, 85-91.	1.5	19

#	Article	IF	CITATIONS
73	Transient ischaemic attack and ischaemic stroke: constructing episodes of care using hospital claims data. BMC Research Notes, 2013, 6, 128.	0.6	7
74	Does antidepressant medication use affect persistence with diabetes medicines?. Pharmacoepidemiology and Drug Safety, 2013, 22, 615-622.	0.9	18
75	Comorbid Diabetes and COPD. Diabetes Care, 2013, 36, 3009-3014.	4.3	48
76	Corticosteroids in diabetes and chronic obstructive pulmonary disease: a therapeutic balancing act. Diabetes Management, 2013, 3, 353-355.	0.5	0
77	Prevalence of preventable medication-related hospitalizations in Australia: an opportunity to reduce harm. International Journal for Quality in Health Care, 2012, 24, 239-249.	0.9	61
78	Chronic disease management: does the disease affect likelihood of care planning?. Australian Health Review, 2012, 36, 419.	0.5	9
79	Co-Morbidity and Potential Treatment Conflicts in Elderly Heart Failure Patients. Drugs and Aging, 2011, 28, 575-581.	1.3	36
80	The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes. Diabetes Research and Clinical Practice, 2011, 91, 115-120.	1.1	5
81	Multimorbidity Research Challenges: Where to Go from Here?. Journal of Comorbidity, 2011, 1, 8-10.	3.9	31
82	Stroke risk and NSAIDs: an Australian populationâ€based study. Medical Journal of Australia, 2011, 195, 525-529.	0.8	42
83	Multimorbidity, care complexity and prescribing for the elderly. Aging Health, 2011, 7, 695-705.	0.3	39
84	Ageing well: Improving the management of patients with multiple chronic health problems. Australasian Journal on Ageing, 2011, 30, 32-37.	0.4	22
85	Major bleeding risk associated with warfarin and coâ€medications in the elderly population. Pharmacoepidemiology and Drug Safety, 2011, 20, 1057-1063.	0.9	47
86	The prescribing cascade. Australian Prescriber, 2011, 34, 162-166.	0.5	58
87	Antidepressant use and depressive symptomatology among older people from the Australian Longitudinal Study of Ageing. International Psychogeriatrics, 2010, 22, 437-444.	0.6	25
88	Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing?. Pharmacoepidemiology and Drug Safety, 2010, 19, 977-982.	0.9	48
89	Influence of Comorbidities on Therapeutic Progression of Diabetes Treatment in Australian Veterans: A Cohort Study. PLoS ONE, 2010, 5, e14024.	1.1	36
90	Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. Journal of Epidemiology and Community Health, 2010, 64, 1036-1042.	2.0	98

#	Article	IF	CITATIONS
91	Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age and Ageing, 2010, 39, 488-494.	0.7	44
92	Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients. Complementary Therapies in Medicine, 2010, 18, 171-174.	1.3	33
93	Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. Diabetes Research and Clinical Practice, 2010, 87, 385-393.	1.1	153
94	Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health, 2008, 8, 221.	1.2	189
95	Characterization of prostaglandin E2 generation through the cyclooxygenase (COX)-2 pathway in human neutrophils. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1235-1245.	1.2	52
96	Response-Driven Combination Therapy with Conventional Disease-Modifying Antirheumatic Drugs Can Achieve High Response Rates in Early Rheumatoid Arthritis with Minimal Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Use. Seminars in Arthritis and Rheumatism, 2007, 37, 99-111.	1.6	63
97	Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 1973-9.	1.0	69
98	Effects of Hypoxia on Monocyte Inflammatory Mediator Production. Journal of Biological Chemistry, 2003, 278, 38607-38616.	1.6	36
99	Up-regulation of Endothelial Cyclooxygenase-2 and Prostanoid Synthesis by Platelets. Journal of Biological Chemistry, 2001, 276, 37839-37845.	1.6	75
100	Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2. Journal of Immunology, 2001, 167, 2831-2838.	0.4	248
101	Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors. Journal of Immunology, 2000, 165, 1605-1611.	0.4	98